论文部分内容阅读
目的探讨重组人脑钠肽(Lrh-BNP)对扩张型心肌病(DCM)及急性心肌梗死(AMI)所致急性心力衰竭(AHF)的治疗效果。方法 DCM或AMI导致的AHF患者133例分为四组:A组,32例,DCM常规治疗;B组,33例,DCM常规治疗+Lrh-BNP治疗;C组,35例,AMI常规治疗;D组,33例,AMI常规治疗+Lrh-BNP治疗。比较治疗后四组患者6-min步行距离、临床症状及心功能改善等情况。结果与A、C组比较,B、D组患者呼吸困难改善明显,6-min步行距离增加,治疗有效例数增加(P<0.05)。D组患者上述指标改善更为明显;D组脑钠肽(BNP)较B、C组明显降低[(367.5±134.6)pg/L vs.(602.5±213.1)pg/L、(489.3±145.5)pg/L](P<0.05)。结论 Lrh-BNP能改善AMI及DCM导致的AHF临床症状及心功能,对AMI后AHF的治疗作用更为明显。
Objective To investigate the therapeutic effect of recombinant human brain natriuretic peptide (Lrh-BNP) on acute cardia failure (AHF) induced by dilated cardiomyopathy (DCM) and acute myocardial infarction (AMI). Methods 133 cases of AHF caused by DCM or AMI were divided into four groups: group A, 32 cases, conventional treatment of DCM; group B, 33 cases, conventional treatment of DCM + Lrh-BNP; group C, 35 cases, AMI routine treatment; D group, 33 cases, AMI conventional therapy + Lrh-BNP treatment. After treatment, the patients in the four groups were compared for 6-min walk distance, clinical symptoms and heart function improvement. Results Compared with group A and group C, dyspnea in group B and D improved obviously, and distance of 6-min walking increased, and the number of effective treatment increased (P <0.05). Compared with B and C group, the BNP in group D was significantly lower than that in group B [(367.5 ± 134.6) pg / L vs. (602.5 ± 213.1) pg / L, (489.3 ± 145.5) pg / L] (P <0.05). Conclusion Lrh-BNP can improve the clinical symptoms and cardiac function of AHF caused by AMI and DCM, and has a more obvious therapeutic effect on AHF after AMI.